Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552976 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
A Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
- 20
- Study locations
NCT05552976: Active Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Bristol-Myers Squibb.
NCT05552976 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 525 participants, above the 290-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05552976, a Phase 3 study of Relapsed or Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Mezigdomide
Study Locations (20)
California
- Local Institution - 0005 - Cerritos
- Local Institution - 0190 - Irvine
- Local Institution - 0187 - Los Angeles
- Local Institution - 0344 - Santa Rosa
- Local Institution - 0339 - Stockton
Florida
- Local Institution - 0341 - Fort Myers
- Local Institution - 0342 - St. Petersburg
- Local Institution - 0340 - West Palm Beach
Georgia
- Local Institution - 0348 - Atlanta
- Local Institution - 0291 - Atlanta
Ohio
- Local Institution - 0322 - Cleveland
- Local Institution - 0172 - Columbus
Alabama
- Local Institution - 0046 - Mobile
Delaware
- Local Institution - 0279 - Newark
Idaho
- Saint Alphonsus Regional Medical Center - Boise
Maryland
- Local Institution - 0289 - Annapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2023-01-10 |
| Est. Completion | 2029-07-25 |
| Phase | Phase 3 |
What the registry record for NCT05552976 still lists
NCT05552976 is an interventional study that assigns participants to a tested intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap, above the 290-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (81% higher).
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT05552976 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05552976 about?
NCT05552976 is a clinical study titled "A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)". The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
What is the current status of trial NCT05552976?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 2023-01-10. Estimated completion is 2029-07-25.
What conditions does trial NCT05552976 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05552976?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Mezigdomide (DRUG).
Who is sponsoring clinical trial NCT05552976?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05552976 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05552976's enrollment target sits among peer trials
525 4th of 10 higher than 7 of 10 other Relapsed or Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
RECRUITING · Phase 3
-
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
ACTIVE NOT RECRUITING · Phase 3
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI